Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab

por van Muijen, Marloes E., Atalay, S., van Vugt, L. J., Vandermaesen, L. M. D., van den Reek, J. M. P. A., de Jong, E. M. G. J.
Publicado 2021

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a...

por van Vugt, L.J., van den Reek, J.M.P.A., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., Kingo, K., Galluzzo, M., Talamonti, M., Lambert, J., Coenen, M.J.H., de Jong, E.M.G.J.
Publicado 2019